Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
XVIVO PERFUSION AB (PUBL) Xvivo Perfusion AB (publ) Stock price
Equities
XVIVO
SE0004840718
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 262.00 SEK | -0.95% | +1.95% | +43.17% | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2023 * | 613 M 59.04 M | Sales 2024 * | 867 M 83.54 M | Capitalization | 8,332 M 803 M |
|---|---|---|---|---|---|
| Net income 2023 * | 37.00 M 3.57 M | Net income 2024 * | 119 M 11.47 M | EV / Sales 2023 * | 12,7x |
| Net cash position 2023 * | 559 M 53.85 M | Net cash position 2024 * | 514 M 49.57 M | EV / Sales 2024 * | 9,02x |
| P/E ratio 2023 * | 218x | P/E ratio 2024 * | 65,0x | Employees | 144 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 74.50% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.95% | ||
| 1 week | +1.95% | ||
| Current month | +12.93% | ||
| 1 month | +14.16% | ||
| 3 months | -6.76% | ||
| 6 months | -6.93% | ||
| Current year | +43.17% |
1 week
257.00
272.50
1 month
221.50272.50
Current year
182.40335.00
1 year
171.60335.00
3 years
127.80459.00
5 years
70.30459.00
10 years
29.80459.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 2012 | |
| Director of Finance/CFO | 38 | - | |
| Chief Tech/Sci/R&D Officer | 56 | 2020 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 59 | 2016 |
| Chairman | 64 | - | |
Lars Henrikson
BRD | Director/Board Member | 68 | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 67 M€ | 0.00% | ||
| 0.08% | 11 M€ | +5.34% | - | |
| 0.05% | 589 M€ | +2.48% | - | |
| 0.05% | 97 M€ | +5.73% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-28 | 262.00 | -0.95% | 26 387 |
| 23-11-27 | 264.50 | 0.00% | 81,434 |
| 23-11-24 | 264.50 | +1.54% | 12,152 |
| 23-11-23 | 260.50 | -2.07% | 12,891 |
| 23-11-22 | 266.00 | +3.50% | 21,412 |
Delayed Quote Nasdaq Stockholm, November 28, 2023 at 11:29 am EST
More quotes
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company's product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
2024-01-25
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
264.50SEK
Average target price
391.67SEK
Spread / Average Target
+48.08%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +43.17% | 797 M $ | |
| -6.82% | 178 B $ | |
| +1.70% | 105 B $ | |
| -6.01% | 68 956 M $ | |
| -0.19% | 44 039 M $ | |
| +22.29% | 40 157 M $ | |
| +29.75% | 38 601 M $ | |
| +51.39% | 26 185 M $ | |
| -10.94% | 23 790 M $ | |
| +27.02% | 23 748 M $ |